[1] HASSING C A,SCHREIBER S L.Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs[J].Curr Opin Chem Biol,1997,1(3):300-308. DOI:10.1016/S1367-5931(97)80066-X. [2] KOUZARIDES T.Histone acetylases and deacetylases in cell proliferation[J].Curr Opin Genet Dev,1999,9:40-48.DOI:10.1016/S0959-437X(99)80006-9. [3] WOLFFE A P.Histone deacetylase-a regulator of transcription[J].Science,1996,272(5260):371-372.DOI:10.1126/science.272.5260.371. [4] BERKLEY E G,QUAOVI H S,ADEGBOYEGA K O.Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed[J].Future Med Chem,2012,4:505-524.DOI:10.4155/fmc.12.3. [5] PAN D S,YANG Q J,FU X,et al.Discovery of an orally active subtype-selective HDAC inhibitor,chidamide,as an epigenetic modulator for cancer treatment[J].Med Chem Commun,2014,5:1789-1796.DOI:10.1039/C4MD00350K. [6] LIU J,WANG T T,WANG X,et al.Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities[J].Med Med Chem Commun,2017,8:1213-1219.DOI:10.1039/C6MD00681G. [7] CHARLES M M,CHRISTOPHER J M,STEPHEN J A,et al.Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and a N-(2-Aminophenyl)-benzamide binding unit[J].J Med Chem,2015,58:6803-6818.DOI:10.1021/acs.jmedchem.5b00545. [8] MICHAEL T B,JOANNE Y,HERMAN Y,et al.The histone deacetylase inhibitor belinostat(PXD101)suppresses bladder cancer cell growth in vitro and in vivo[J].J Trans Med,2007,5:49.DOI:10.1186/1479-5876-5-49. [9] NOVOTNY-DIERMAYR V,SANGTHONGPITAG K,HU C Y,et al.SB939,a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer[J].Mol Cancer Ther,2010,9(3):642-52.DOI:10.1158/1535-7163.MCT-09-0689. [10] DANIEL E,ALFONSO L,HEINZ N.Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives[J].Chem Res Toxicol,2006,19:272-278.DOI:10.1021/tx0502241. [11] THOMAS B,CARMEN B,HEIKE W,et al.Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group[J].Int J Cancer,2007,121(5):1138-1148.DOI:10.1002/ijc.22751. [12] JOOSTEN L A,FLAVIO L,SAJEDA M,et al.Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis[J].Mol Med,2011,17(5-6):369-77.DOI:10.2119/molmed.2011.00058. [13] STUHMER T,ARTS J,CHATTERJEE M,et al.Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585[J].Br J Haematol,2010,149(4):529-36,529-36.DOI:10.1111/j.1365-2141.2010.08126.x. [14] CAI X,QIAN C G.In designing multi-target drugs[M].London: Royal Society of Chemistry,2012:221-242. [15] MOSMANN T.Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays [J].J Immunol Methods,1983,65(1-2):55-63.DOI:10.1016/0022-1759(83)90303-4. [16] ZHANG Q W,LI J Q.Synthesis and biological evaluation of N-(Aminopyridine)benzamide analogues as histone deacetylase inhibitors[J].Bull Koreon Chem Soc,2012,33(2):535-540.DOI:10.5012/bkcs.2012.33.2.535. |